Amsbio has added new cell lines expressing endogenous or recombinant proteins to its portfolio of stable cell lines.
The lines, which are available in a ready-to-use format provide an optimised solution for manufacture of therapeutic and diagnostic protein, and also for applications in drug screening, pharmacological research and toxicological studies.
The portfolio of ready-to-use stable cell lines available from Amsbio includes Receptors (RAR a, IGF1 Receptor, Motilin Receptor MLNR…), Ion channels (CFTR, Nav1.7, Kv1.5…), Cell signaling (Notch, JNK, NF-?B, ERK…), Phosphodiesterases (aequorin, CNGA2, PDE1B…), Stem cell related (LGR5, OCT4, LIN28), Fluorescent (GFP, RFP, CFP, YFP), TetR, Luciferase, CRE recombinase/reporter, p53 and DNA repair gene knock-down cell lines (PARP1, MUTYH, MSH2, MLH1, XRCC6, BRCA1, NBS1…).
Amsbio also has extensive experience in cell line development and developing demanding custom cell lines for academic, biotechnology and pharmaceutical organisations. Using a lentiviral system, Amsbio scientists can establish an optimised cell line according to specification.
All Amsbio custom cell lines are designed specifically to meet client specification as well as rigorous internal QC criteria, within demanding timelines.
